213202-12-1

Basic information

• Product Name: (S)-N-((S)-1-phenylethyl)-1-(3-(trifluoromethyl)phenyl)propan-2-amine
• Synonyms: (S)-N-((S)-1-phenylethyl)-1-(3-(trifluoromethyl)phenyl)propan-2-amine
• CAS NO: 213202-12-1
• Molecular Weight: 343.82
• Mol File: 213202-12-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-N-((S)-1-phenylethyl)-1-(3-(trifluoromethyl)phenyl)propan-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-((S)-1-phenylethyl)-1-(3-(trifluoromethyl)phenyl)propan-2-amine(213202-12-1)
• EPA Substance Registry System: (S)-N-((S)-1-phenylethyl)-1-(3-(trifluoromethyl)phenyl)propan-2-amine(213202-12-1)

Safety Data

• Hazardous Substances Data: 213202-12-1(Hazardous Substances Data)

Upstream product

• 21906-39-8 3-(trifluoromethyl)phenylacetone 
• 7440-02-0 nickel 
• 2627-86-3 (S)-1-phenyl-ethylamine 

Downstream Products

• 19036-73-8 (S)-norfenfluramine 

Relevant articles and documents

METHOD FOR TREATING EPILEPSY

In certain embodiments, the present disclosure is directed to methods and uses for treating a mammal having an epileptic seizure disorder or being at risk for having an epileptic seizure disorder, comprising administering certain herein disclosed isolated fenfluramine enantiomers that are surprisingly effective as anti-epilepsy drugs (AEDs), despite having lower anti-seizure potency than fenfluramine racemate, by virtue of also being less cardiotoxic than fenfluramine racemate. Preferred embodiments contemplate treatment of Dravet syndrome; other preferred embodiments contemplate treatment of other epileptic seizure disorders.

Process for the production of the isomers (R) and (S)-α-methyl-3(trifluoromethyl)benzeneethanamine

Process for the production of the isomers (R) and (S)-α-methyl-3-(trifluoromethyl)benzeneethanamine, the second being useful as intermediate in the synthesis of the anorexic drug dexfenfluramine (INN), which comprises carrying out a stereospecific reductive amination of 1-(3-trifluoromethyl)phenyl-2-propanone with (R) or (S)-α-methylbenzylamine under a hydrogen atmosphere in the presence of a catalyst and debenzylating the resulting diastereoisomer (R),(R) or (S),(S)-N-(1-phenylethyl)-α-methyl-3-(trifluoromethyl)benzeneethanamine by treatment with hydrogen and a catalyst.